The prospective proof-of-concept study enrolled 40 client-owned dogs diagnosed with unilateral suspected cranial cruciate disease and osteoarthritis. Each dog received a single intra-articular injection of the collagen-elastin hydrogel microparticulate biomaterial and was evaluated over an 84-day period using serial clinical examinations, the modified Glasgow Composite Pain Scale (mGCPS), clinician assessments, and owner-reported outcome measures.

Among the findings reported by the investigators:

  • 55% of enrolled dogs achieved at least a 25% improvement in the study's primary endpoint, the modified Glasgow Composite Pain Scale (mGCPS).
  • Statistically significant improvements were observed across all additional subjective clinician- and owner-assessed outcome measures during the study period.
  • The investigators concluded that the collagen-elastin hydrogel microparticulate biomaterial demonstrated feasibility for use in dogs with suspected cranial cruciate disease and stifle osteoarthritis within the subjective parameters evaluated, while noting that further studies utilizing objective outcome measures are warranted.

While the investigators concluded that additional studies utilizing objective outcome measures are warranted, the statistically significant improvements observed across multiple clinician- and owner-assessed outcome measures provide encouraging support for continued evaluation of Spryng® as an innovative treatment option for dogs suffering from osteoarthritis associated with cranial cruciate disease.

As disclosed in the published manuscript, the study was funded by PetVivo Holdings, Inc. and conducted by the participating investigators. The findings were subsequently evaluated and accepted for publication through the independent peer-review process of Veterinary Record.